Healio: DARE-19: Dapagliflozin could target key mechanisms activated in COVID-19 | Saint Luke's Health System
Otavio Berwanger on LinkedIn: Our DARE-19 trial (dapagliflozin in 1250 patients with COVID-19 and high…
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications | Saint Luke's Health System
![ADA 2021: "DARE-19 demonstrates the safety of Dapagliflozin in patients with acute illness"|ADA 2021: "DARE-19 demonstrates the safety of Dapagliflozin in patients with acute illness" ADA 2021: "DARE-19 demonstrates the safety of Dapagliflozin in patients with acute illness"|ADA 2021: "DARE-19 demonstrates the safety of Dapagliflozin in patients with acute illness"](https://storage.googleapis.com/web-assets/june_27_kosiborod_1/june_27_kosiborod_2/june_27_kosiborod_2-original.jpg)
ADA 2021: "DARE-19 demonstrates the safety of Dapagliflozin in patients with acute illness"|ADA 2021: "DARE-19 demonstrates the safety of Dapagliflozin in patients with acute illness"
![Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213858721001807-gr1.gif)
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial,Therapeutic Innovation & Regulatory Science - X-MOL
![Enrique Santas on X: "DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile 🎯 Do not discontinue SGLT2i in 🏥 for #COVID19 Full slideset available Enrique Santas on X: "DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile 🎯 Do not discontinue SGLT2i in 🏥 for #COVID19 Full slideset available](https://pbs.twimg.com/media/E1gy0t0WEAAPTEW.jpg)
Enrique Santas on X: "DARE-19 trial #ACC21 @ACCinTouch Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile 🎯 Do not discontinue SGLT2i in 🏥 for #COVID19 Full slideset available
![Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial | Therapeutic Innovation & Regulatory Science Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial | Therapeutic Innovation & Regulatory Science](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43441-022-00420-1/MediaObjects/43441_2022_420_Fig1_HTML.png)
Design and Analysis of Studies Based on Hierarchical Composite Endpoints: Insights from the DARE-19 Trial | Therapeutic Innovation & Regulatory Science
![Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213858721001807-gr3.jpg)
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
![DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News](https://www.adameetingnews.org/wp-content/uploads/2021/05/21-ADA-Kosiborod-Mikhail-760x488-1.jpg)
DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News
Kansas City Business Journal: Saint Luke's cardiologist leads trial to see if diabetes drug can prevent serious COVID-19 complications | Saint Luke's Health System
![ESC 365 - Discussant review - Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19 ESC 365 - Discussant review - Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19](https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6169276219001/6cd0850c-45fb-4a71-a9ec-043f2ed29e3d/main/1200x630/3m19s626ms/match/image.jpg)
ESC 365 - Discussant review - Prospective Meta-Analysis of SGLT2 Inhibitor Randomized Trials in COVID-19
![DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News](https://www.adameetingnews.org/wp-content/uploads/2021/05/21-ADA-Kosiborod-Mikhail-400x600-1-200x300.jpg)
DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19 - ADA Meeting News
![Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213858721001807-gr2.jpg)
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect
![Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2213858721X00095-cov150h.gif)